FTC Sues PBMs For Policies That Led To Inflated Insulin Costs
WASHINGTON, D.C. — The Federal Trade Commission on Sept. 20 filed an administrative complaint against three prescription drug benefit managers (PBMs) accusing them of creating “a perverse drug rebate system that...To view the full article, register now.
Already a subscriber? Click here to view full article